RussianPatents.com

Method for steroid profiling in dope test of sportsmen

Method for steroid profiling in dope test of sportsmen
IPC classes for russian patent Method for steroid profiling in dope test of sportsmen (RU 2467331):
Another patents in same IPC classes:
Method of determining clinical effectiveness in cervical cancer / 2464576
One week after the termination of polychemotherapy, daily urine is examined for the amount of cortisol and cortisone, while blood is examined for adrenocorticotropic hormone. It is followed by calculating the relation of total cortisol and cortisone to adrenocorticotropic hormone. If the derived value is 0.74 and higher, high responsiveness to chemopreparations is stated.
Method for describing nature of arrested sexual development in boys in puberty with growth retardation / 2462720
Examination results are used to detect boys with the absence or insufficiency of blood concentrations of at least two of three hormones (luteinising hormone, follicle-stimulating hormone, total testosterone) to be used for the clinical course of transcranial magnetic therapy. The concentration of all hormones are evaluated in 1-1.5 months, and if observing increase of the concentrations of at least two hormones, including testosterone by min. 25% from the initial values, a functional nature of arrested sexual development is stated. If observing no increase or increase of the concentrations of two hormones, including testosterone by max. 25% from the initial values, an organic nature of arrested sexual development is stated.
Diagnostic technique for idiopathic nasal breathing irregularities in pregnant women Diagnostic technique for idiopathic nasal breathing irregularities in pregnant women / 2456604
Blood serum of a pregnant woman is examined for the oestradiol concentration by enzyme-linked immunosorbent assay. Observing the oestradiol concentrations exceeding normal values according to weeks of gestation in 1.4 times and more enables stating idiopathic nasal breathing irregularities accompanying a period of pregnancy.
Method for prediction of level of efficiency of reduction of manifestation severity of atopic dermatitis / 2453851
Pre-therapy blood plasma is analysed for immunoglobulin E, adrenocorticotrophin and endorphin, the index SCORAD dynamics is determined by formula: Dsk=1.34147-0.000820741*IgE-0.00382642*ACTP+0.0209401*endorphin wherein IgE is the level of acute blood plasma immunoglobulin E mIU/ml; ACTP is the level of acute blood plasma adrenocorticotrophin ng/l. If observing the Dsk value exceeding 1.18, a prognosis of improving clinical dynamics of recovery is favourable; the conventional therapy is considered to be sufficient. The Dsk value being equal to 1.18 or less, the improving clinical dynamics of recovery is unfavourable, the intensified therapeutic scheme for atopic dermatitis is considered to be preferential.
Method for identification and classification of 3-oxosteroids and their metabolites in doping test of sportsmen Method for identification and classification of 3-oxosteroids and their metabolites in doping test of sportsmen / 2452967
Blood plasma is examined for the presence and the position of double bonds and the related differences in structural characteristics. Common and examined steroids are chemically modified by a carboxyl group (oximes); their mass spectra are read out and recorded; characteristic ions (lc) and neutral loss (Do) are specified in the mass spectra. The specified lc and Do values are related to those specific for common 3-oxosteroid oximes by the absolute value. Herewith it is only the similar lc and Do values from both sides differing by 0.3% and less that are taken into consideration; the comparison results are used to identify 3-oxosteroid oximes.
Method of antenatal prediction of consequences of perinatal lesions of nervous system in children / 2449287
Clinical examination of pregnant woman is carried out, additionally performed are Stange's and Hench's functional respiratory tests in early period at terms of 11-19, 21-29, 31-39 weeks of gestation period, also in dynamics in I and III trimesters determined are indices of blood hormonal spectrum: T4, TSH, T3, cortisole, vitamin E, insulin, indices of lipid peroxidation and antioxidative blood activity, blood indices - hemoglobin, platelets, total protein, fibrinogen. Analysis of risk factors is carried out, their gradations and numerical values are determined and prognostic coefficients S1 and S2 are calculated by formulas. If S1>S2, presence of moderate or severe CNS lesion in children at the age of 4 is predicted. If S1<S2, presence of light degree of severity, or absence of consequences of CNS lesion in children at the age of 4 is predicted.
Method for prediction of dysthyroidism / 2446401
Method involves woman's pre-delivery blood serum examination for nitrogen oxide and relaxin that is followed by calculation of the NO/relaxin relation. If the relation is 3.6 and less, dysthyroidism is predicted.
Method of predicting development of cerebral metastases in case of lung cancer in women / 2439579
In women in tissue of lung malignant tumour after radical surgery in pulmonectomy volume and in intact lung tissue, obtained from ablated from lung section of the same lung, level of progesterone is determined. If it reduces in tumour in 5 times and more relative the level of progesterone in intact lung tissue, development of cerebral lung cancer metastases in women within the term from 3 to 8 months is predicted.
Method of diagnosing androgenic deficiency / 2439578
In blood serum bioavailable testosterone fraction bound to albumin is determined. If its value is lower than 185.7 pg/ml, disease is diagnosed.
Method of predicting survival potential of patients with malignant gliomas Method of predicting survival potential of patients with malignant gliomas / 2439577
In patient's urine content of 6-sulfatoximelatonin is determined. If determined content of 6-sulfatoximelatonin after operation before complex treatment equals 292.7 nmol/ml survival to 2.3±0.5 months is predicted, if 22.4 nmol/ml is determined, survival for more than 12 months is predicted. If after chemical therapy determined content of 6-sulfatoximelatonin equals 268.2 nmll/ml, predicted survival time equals to 2.1±0.6 months, if content is 32.8 nmol/ml - more than 12 months. If after a month after treatment determined content of 6-sulfatoximelatonin equals 479.3 nmol/ml predicted is survival for 1.2±0.5 months, in case of 37.4 nmol/ml - survival for more than 12 months.
Method for assessing osteocyte involvement in bone matrix mineralisation Method for assessing osteocyte involvement in bone matrix mineralisation / 2466408
Osteons and intermediate lamellas are delineated and framed as members of analysis; osteocyte lacunae are numbered in each formed image; total number is presented, as well as a number of lacunae containing minerals in an amorphous phase. A percentage of the latter is described as a coefficient of osteocyte involvement in bone matrix mineralisation. If the minerals in the amorphous phase are found in less than 30% of lacunae, mineralisation activity of osteocyte is considered to be low. The presence of the amorphous minerals in 30-80% of lacunae shows moderate activity, and if more than 80% of lacunae contain the minerals in the amorphous phase, high activity is stated.
Method for quantitative assessment of assimilated drug Method for quantitative assessment of assimilated drug / 2464564
What is described is a method for the quantitative assessment of an assimilated drug involving the accompanying uptake of a visualising substance, and the studies conducted over a certain period of time wherein the visualising substance is presented by a fluorescent food additive mixed with the main drug in constant weight proportions F:X=φ:(1-φ) wherein F is a dose of the fluorescent food additive mg/kg of weight a day, X is a dose of the drug mg/kg of weight a day prescribed by a doctor, φ is a weight fraction of the fluorescent food additive while the studies are conducted with the use of spectrophotometry before and 12-72 h after the uptake of the mixture with the specified epithelial areas being exposed to laser of wave length 532 nm, continuous power 5÷10 mWt; fluorescence intensity is recorded within the range of wave lengths 650-690 nm. - J0(λ) and J1(λ) respectively, while the amount of the drug is described by formula: wherein CJ(S) is a dependence functional of fluorescence signal integral of the used visualising substance within its characteristic range of wave lengths found by the calibration graph for chlorophyll pigment as the fluorescent food additive wherein the value SJ calculated by formula: wherein λ is wave length, nm, while J0(λ). and J1(λ). are the fluorescence power values (in the identical standard optical units) measured before the studies and during a period of reference time t (hour) respectively.
Method of diagnosing cancer and potential resistance of malignant cells to hypoxia Method of diagnosing cancer and potential resistance of malignant cells to hypoxia / 2463963
Invention relates to field of medicine, namely to oncology. To diagnose cancer and potential resistance of malignant cells to hypoxia, prepared is cell imprint or suspension of cells, for which conditions of hypoxia are created and spectro-flowmetric analysis of said cells in dynamics of development of process of photodestruction of NAD(P)H fluorescence is performed. Conclusion about presence of tumour cells and their potential resistance to hypoxia is made by increase of NAD(P)H fluorescence intensity in conditions of darkness. Conditions of hypoxia are created by placement of cell suspension or cell imprint between two glasses for cytologic analysis. Spectro-flowmetric analysis is carried out in the range 440-470 nm, with length of excitation wave 365-370 nm.
Method for prediction of degree of severity of hypoxic perinatal cns damage in newborns / 2463603
What is described is a method for prediction of a degree of severity of perinatal hypoxic central nervous system damage in newborns by studying of biochemical blood plasma analysis wherein umbilical blood plasma is evaluated by the level of peroxinitrite, and if the value is 133.6-258 nmole/l, a moderate degree of severity of the CNS damage is predicted, while the values 259 nmole/l and higher shows a severe degree.
Method for prediction length of postoperative intestinal paresis accompanying intestinal obstruction Method for prediction length of postoperative intestinal paresis accompanying intestinal obstruction / 2463602
What is presented is a diagnostic technique for the length of postoperative intestinal paresis in the patients suffering intestinal obstruction by blood examination. Patient's blood serum is examined for the preoperative intensity of spontaneous and iron-induced chemoluminescence, and the values of spontaneous luminosity ≤1.32 standard units, fast burst height ≤2.13 standard units and slow flare light sum ≤4.98 standard units, the length of intestinal paresis is diagnosed to be no more than 2.5 days. The values of spontaneous luminosity > 1.32 to 2.08 standard units, fast burst height > 2.13 up to 2.64 standard units and slow flare light sum > 4.98 to 7.49 standard units, the length of intestinal paresis is predicted to be > 2.5 to 3.5 days. If observing the higher values, the length of intestinal paresis is expected to be > 3.5 days.
Method for evaluating clinical effectiveness in lipidemia / 2462718
Invention describes a method for evaluating the clinical effectiveness in lipidemia by pre- and post-therapeutic blood serum analysis wherein the assay is preceded by three blood serum freezing and thawing procedures for 20 minutes and 10 minutes respectively followed by evaluation of apolipoprotein B, lipopolyprotein (a), their relation, total cholesterol and if observing increase of the apolipoprotein B to lipopolyprotein (a) relation by 50% and more and decrease of total cholesterol by 30% and more as compared with the initial level, the lipidemia treatment is stated to be effective. The use of the presented method provides higher accuracy of evaluating the clinical effectiveness in lipidemia.
Method for prediction of clinical course of border psychic disorders / 2455646
Patients' blood serum is examined for the pre-therapeutic mean molecule spectrum. If a mean molecule fractions described as optical absorption E at wave length 254 nm exceed 0.35 standard units, and an aromaticity index (AI) described as a relation of the optical absorption E at wave length 280 nm to the optical absorption E at wave length 254 nm is max. 0.8, developing dissociative symptoms and signs are predicted.
Method for prediction of developing bacterial complication of staphylococcal aetiology following influenza Method for prediction of developing bacterial complication of staphylococcal aetiology following influenza / 2452960
For the purpose of prediction of developing bacterial complication of a staphylococcal aetiology following influenza, the pure culture S. aureus is recovered from nasopharyngeal mucosal microflora to determine hemolytic activity (HA), antilysozyme activity (ALA), then S.aureus is co-incubated in vitro with type B influenza; S.aureus is analysed again for hemolytic and antilysozyme activity, and increasing S.aureus HA by 1 mm and more and/or ALA by 1 mcg/ml and more after co-incubation, a developing bacterial complication is predicted.
Diagnostic technique for stage three alcoholism / 2450269
Male patients with stage III chronic alcoholism aged 40 to 60 years old are examined for activity of saliva superoxide dismutase. If observing decreasing SOD activity by 50 % and more of the age norm, the onset of the stage of the disease is diagnosed.
Method for prediction of risk of decreasing body resistance to acute respiratory diseases in children between ages of 3 to 7 by immunological criteria Method for prediction of risk of decreasing body resistance to acute respiratory diseases in children between ages of 3 to 7 by immunological criteria / 2445630
Child's peripheral blood is examined to evaluate the percentage of lymphocytes and the concentration of immunoglobulin M by turbidimetric method in g/l. If the concentration of immunoglobulin M is higher than 1.125 g/l, while the percentage of lymphocytes is higher than 47% (oppositely directed deviances), then a child is referred to a risk group with decreased body resistance to acute respiratory diseases.
Method for prediction of risk of developing early occupational allergic dermatoses Method for prediction of risk of developing early occupational allergic dermatoses / 2467330
Invention refers to medicine, and concerns a method for prediction of a risk of developing early occupational allergic dermatoses. The method involves venous blood sampling, genetic material recovery to be examined for polymorphy version A4889G of cytochrome P-450 1A1 by polymerase chain reaction followed by real-time high throughput sequencing. Conducting PCR requires specific primers C1A1-F Biotin - ggT gTT Aag TgA gAA ggT gAT T and C1A1-R Cag gAT AgC Cag gAA gAg AAA to be used; while high throughput sequencing involves specific primer C1A1-S ACC TCC Cag Cgg gCA A. If the derived pyrogram in position 4889 shows no adenine for guanine substitution and body exposure to an occupational hazard, the risk of developing early occupational allergic dermatoses less than 40% is predicted. If observing heterozygous version Cyp1A1*2C caused by adenine for guanine substitution in a nucleotide sequence in position 4889, and body exposure to said occupational hazard, the risk of 40%÷80% of developing early occupational allergic dermatoses is predicted.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely sports medicine, and may be used for steroid profiling in dope test of sportsmen. That is ensured by urine sample hydrolysis by a mixture of two enzymes: β-glucuronidase E.coli and arylsulphatase H.pomatia in volume ratio 1:1 to 1:3 in the presence of a citrated buffer solution and an internal standard. The hydrolysate is separated, derivatised that is followed by chromatic/mass-spectral analysis of the sample and recording of the derived results and stating the presence of endogenic steroids (ES). The ES value is determined in a sportsman for at least 10-15 times every 10-12 days. The analysis results are used to set minimum and maximum values of each of the derived ES. Said values are accepted to be a confidence range, and a steroid profile of the sportsman is drawn as a set of confidence ranges of all found ES.

EFFECT: invention provides steroid profiling, extending a variety of the stated ES and ensuring a higher degree of reliability of stating the ES.

2 cl, 12 dwg, 5 tbl, 5 ex

 

The invention relates to medicine, namely to clinical chemistry, in particular to methods for determining levels of endogenous steroids in the body, and can be used, for example, when the doping control athletes, and especially when preparing the athlete biological passport.

A known method for determining endogenous steroids (ES) colorimetric methods of analysis [1].

The way this relates to the methods of qualitative analysis and, accordingly allows to determine only the presence of ES, without determining their structural characteristics and nature. Moreover, according to the described method it is possible to analyze only objects with a very high content of ES.

There are also known methods for determining ES by gas chromatography coupled with mass spectrometry [2-4].

A common shortcoming of such methods is laborious and lengthy in time stage of obtaining volatile derivatives for ES, which significantly complicates the course of the analysis, increases the duration and cost of the process.

The closest in technical essence and the achieved result to the claimed method is GC-MS method for determining ES in human urine by gas chromatography coupled with mass spectrometry (GC-MS) [5].

At the specified method sample the eyes add phosphate buffer solution, an internal standard, and the enzyme β-glucuronidaseE.coli). The mixture is stirred and incubated and after hydrolysis add carbonate buffer solution and diethyl ether, then the organic layer was separated after centrifugation, evaporated to dryness, derivatized and analyze by method GC/MS.

The main disadvantage of this method is the low reliability of the determination of RN (in particular, when determining steroid profile) and high threshold (for example, to epitestosterone 10-12 ng/ml), because steroids are excreted in the urine in the form of glucuronidase and sulfates, and analysis are only glucuronidase.

The technical result, which directed the establishment of this invention is to increase the degree of reliability of determination of ES, in particular when determining steroid profile by lowering the threshold and expanding the range defined ES and, accordingly, determine the steroid profile.

The technical result is achieved by the fact that in the process of preparation of the hydrolysis of the analyzed sample of urine are a mixture of two enzymes: β-glucuronidaseE. coliand UkrainianH.pomatiain the ratio from 1:1 to 3:1 and as a buffer solution using citrate buffer solution, while the athlete determine Aut ES at least 10-15 times with intervals between tests not less than 10-12 days test results establish the minimum and maximum quantitative value for each of the identified ES, accept the specified values for the confidence interval and build longitudinal profile of the athlete as a set of confidence intervals all found ES.

It is known that GC/MS analysis of the ES it is necessary to spend several stages of sample preparation, because the excretion of ES in the urine occurs after phase II metabolism, namely conjugation, during which the formed esters of compounds and steroids are excreted in the urine in the form of glucuronidase and sulfates. Some steroids, such as Androsterone, etiocholanolone, testosterone and epitestosterone may appear in the urine in the form of sulfates with respect to the glucuronidase to 1:1. Other steroids, such as dehydroepiandrosterone, Androstenedione, estrone, estriol, can appear in the urine mainly in the form of sulfates. In turn sulfate are of interest for the purposes of doping control not only because of the endogenous ES, but also for the reason that some steroids constitute the most long-lived metabolites it is in the sulfate fraction and therefore they can be detected in biological fluids during, for example, not 6 hours, and within 18 or 24 hours, which should improve the reliability of the confirmation of doping athlete. However, men who in the present time, the concentration of the main endogenous ES, such as testosterone, epitestosterone, Androsterone, etiocholanolone, dehydroepiandrosterone and others, according to the standards WADA calculated from glucuronidase relevant ES [6]. Currently, there are about thirty ES man, but the authors based on their knowledge and experience, argue that to determine reliable steroid profile analytically, it is sufficient to explore the most typical 8-12 ES.

When implementing the claimed invention, the apparatus registration process can be used, for example, the chromatograph Agilent 6890, coupled with mass-selective detector Agilent 5973N with electron ionization (70 eV), column Restek Rxi - 1ms (length 12 m, internal diameter of 0.20 mm, the thickness of the stationary phase of 0.33 μm).

Temperature program can be set with the following parameters: rise from 188°C to 232°C at a rate of 2°C/min, then from 232°C to 300°C at 12°C/min, isotherm 5,33 min when the volume of injected sample 2 ál of the divide flow (1:20), injector temperature of 280°C. the carrier Gas - helium (0.6 ml/min). The temperature of the ion source is 230°C, the temperature transition line - 290°C, quadrupole - 150°C, scan rate was 1.69 cycles/sec, the mass range in the full scan mode - 50-600 Amu

As reagents and materials can be used, for example,N-methyl-N-(trimethylsilyl)-t is iterated (MSTFA), β-glucuronidase fromH.pomatia,arylsulfatase fromH.pomatiaand sodium acetate (Sigma-Aldrich, USA); standard samples of testosterone, epitestosterone, Androsterone, etiocholanolone, dihydrotestosterone, Androstenedione, estrone, estriol, 11β-hydroxyandrostenedione, 11β-hydroxyethykellulose and dehydroepiandrosterone (Steraloids, Newport, USA); methanol, hydrochloric acid and acetic acid (Merck, Germany); potassium dihydrophosphate, phosphate, sodium and ammonium iodide (Riedel-de-Haën, Germany); potassium carbonate, potassium bicarbonate and sodium sulfate (Hemmed, Russia); diethyl ether (Medienraum, Russia); 1,4-dithio-DL-trital (DTT), imidazole (Fluka, Switzerland); potassium citrate (Alfa Aesar, USA); internal standard - methyltestosterone, D4-androstene-glucuronide and D5-etiocholanolone (LGC Standards, UK); deionized water (MilliQ, Germany).

Of course, there may be used the equipment, materials and reagents from other manufacturers, provided, however, that the qualitative characteristics they will ensure the reproducibility of the results of research in the scope of the claimed patent claims.

As accessories can be used: automatic shaker firm Glas-Col®, USA - for JJA; centrifuge brand Rotina 46R company Hettich (Germany) to obtain the contrast of the boundary surface between the organic and aqueous phases;- privately company Banstead Inc. (USA), combined with a nitrogen generator Mistral-4 firms Schmidlin-DBS AG (Czech Republic) for evaporation of the organic extract. As extractant for IGE can be used methyl tertiary butyl ether (MTBE). As pH regulators may be used sodium bicarbonate and potassium carbonate.

The invention can be implemented as follows.

Prepare urine samples, add them in buffer solution, internal standard (methyltestosterone, for a final concentration of 500 ng/ml of urine), the exact amount of enzyme or mixture of enzymes. The mixture is then stirred and incubated at an elevated temperature for 1.0 to 1.5 hours. After hydrolysis the mixture was added carbonate buffer solution (pH 10,4) and diethyl ether, shake for 3-10 min, centrifuged, separated the organic layer and evaporated it to dryness and derivatized solution of MSTFA/NH4I/DTT by heating within 20-40 minutes, derivatized transferred into the vial and analyzed by method GC/MS. Remove and register chromatographic and mass spectrometric characteristics of the substances standards and all solutions and samples (detects at least three characteristic ions of each reference substance, determine the retention time, molecular mass precursor ions, characteristic ions, the lower limit of detection) and the resulting re is ulitity injected into the software, for example ChemStation company Agillent, USA.

For a better understanding of the invention can be illustrated by, but is not exhausted by the following specific examples of its implementation.

Example 1

Prepare standard solutions of analytes (1 mg/ml), particularly testosterone, epitestosterone, Androsterone, etiocholanolone, dihydrotestosterone, Androstenedione, estrone, estriol, 11β-hydroxyandrostenedione, 11β-hydroxyethykellulose and dehydroepiandrosterone. Working solutions are prepared by dissolving accurately weighed ES - standards in methanol. Next get a working solution by diluting the standard solutions to the content of 10 μg/ml Standard solutions of each of the ESTER (1 mg/ml) prepared by dissolving accurately weighed in the exact volume of methanol. To 3 ml of urine (from previously prepared samples) add 1 ml of buffer solution, 30 μl of internal standard (MT, for a final concentration of 500 ng/ml of urine), the exact amount of the mixture of enzymes. The mixture is stirred and incubated at 55°C for 1 hour 10 minutes. After hydrolysis, add 1 ml of carbonate buffer solution (pH 10,4) and 5 ml of diethyl ether. Shake for five minutes, centrifuged at 3000 rpm for 5 min; the organic layer is separated, evaporated to dryness at 70°C for 40 minutes and spend the derivatization of 50 ál of a solution of MSTFA/NH4I/DTT (1000:3:2) when heated to 70°C in t is within 30 minutes, the solution is transferred into the vial and analyzed further by method GC/MS (parameters of the analytical procedure described above).

The content of individual ES in urine is determined in the same manner and under the same parameters as in the standard solutions, with the exception that the hydrolysis of these samples are in the following order (see Table 1).

Table 1

The urine sample Enzyme The buffer Found ES (ng/ml)
1 E.coli + helix pomatia citrate testosterone, epitestosterone, Androsterone, etiocholanolone, dihydrotestosterone, Androstenedione, estrone, estriol, 11β-hydroxyandrost, 11β-gidroxiatilkrahmala
1A E.coli phosphate testosterone, epitestosterone, Androsterone, etiocholanolone, dihydrotestosteron, 11β-hydroxyandrost, 11β-gidroxiatilkrahmala
2 E.coli + helix pomatia citrate testosterone, epitestosterone, Androsterone, etiocholanolone, money is groundstation, Androstenedione, estrone, estriol, 11β-hydroxyandrost, 11β-gidroxiatilkrahmala
3 E.coli + helix pomatia citrate testosterone, epitestosterone, Androsterone, etiocholanolone, dihydrotestosterone, Androstenedione, estrone, estriol, 11β-hydroxyandrost, 11β-gidroxiatilkrahmala
3A E.coli phosphate testosterone, epitestosterone, Androsterone, etiocholanolone, estrone, 11β-hydroxyandrost, 11β-gidroxiatilkrahmala

Presented in Table 1 results becomes obvious that the use for hydrolysis of a mixture of enzymes E. coli + helix pomatia in citrate buffer allows to expand the range defined ES, as well as significantly reduce the detection threshold of these compounds. In particular, it can be seen from the comparison of the results obtained in Table 2 (the number in the sample ES ng/ml).

Table 2

td align="center"> 0
ES The urine sample 1 The urine sample 1A The urine sample 2 The urine sample 3 The urine sample 3A The notes.
Testosterone 35 20 52 110 93
Epitestosterone 51 40 36 42 40
Androstene 1280 850 7320 10850 5120
Etiocholanolone 970 550 5600 7400 4500
Dihydrotestosteron 120 15 74 12 0
Androstenedione 24 0 8 22
Estrone 17 2 21 11 1
Estriol 12 0 5 10 0
11β-Hydroxyandrost 400 300 870 610 560
11β-Gidroxiatilkrahmala 250 213 405 540 470

Example 2 (comparative)

For comparison, carried out the analyses of the urine samples subjected to hydrolysis at various combinations of enzymes and buffers (see Table 3).

Table 3

1 The enzyme of E.coli The phosphate buffer On WADA
2 The mixture of enzymes E. coli+helix pomatia The buffer is citrate The claimed invention
3 The enzyme of E.coli The buffer is citrate To compare
4 The helix pomatia enzyme The phosphate buffer To compare
5 The helix pomatia enzyme The buffer is citrate To compare

The results for the studied series ES are shown in Fig.1-5.

From the presented illustrative materials implies that when used as a hydrolysing environment of a mixture of enzymes (E. coli+helix pomatia) in citrate buffer lower limit of detection was investigated ES compared with the known (unit, or 100%) is reduced at least to 0.8-0,35 (i.e. 1.2-1.65 times).

Example 3

Prepare the sample of urine, add in a buffer solution, internal standard (MT, for a final concentration of 500 ng/ml of urine), the exact amount of enzyme or mixture of enzymes. The mixture is then stirred and incubated at an elevated temperature during 1,0 -1,5 hour and further procedures which have carried out as in Example 1, including equipment and conditions for GC/MS analysis except that the urine sample is divided into five aliquot and each aliquot is subjected to hydrolysis under the following conditions (table 4).

Table 4

An aliquot The E.coli enzyme (ml) Helix pomatia (ml) Note
1 1,0 0,7
2 1,0 1,0
3 1,0 2,0
4 1,0 3,0
5 1,0 3,5

The results of determination of ES, in particular etiocholanolone shown in figure 6.

From figure 6 it follows that the optimal ratio of the amount of enzyme is 1:2 to 1:3. Output ratio for the stated limits reduces the expected result identify ES.

Example 4 (Definition of Stero the underwater profile)

Determine the longitudinal profile of the volunteer (biathlete, male, 23 years). Just taken 17 tests with an interval between analyses 10-15 days. It should be noted that the athlete for the entire observation period (220 days) did not take drugs and not used in a transfusion of blood. Confidence interval values of each specific ES set as the difference between the minimum and maximum values specified ES in time (in this case, during the time of observation - 220 days and according to the 17 analyses). Fig.7-10 presents the steroid profiles of athletes in the dehydroepiandrosterone, epitestosterone and testosterone and estriol, respectively. In other investigational ES steroid profiles are presented in Table 5. To determine steroid profile is selected by two minimum and maximum values of the total number of 17 values.

Table 5

№№ p/p Steroid Min. Val., ng/ml Maxim. Val., ng/ml Confidence interval
1 androstene 4700; 4680 8500; 8350 4680 - 8500
2 etiocholanolone 3750; 3800 7700; 7500 3750 - 7700
3 Androstenedione 6,5; 6,3 25,0; 26,5 6,3 - 26,5
4 estrone 12,5; to 12.0 28,5; 28,0 12,0 - 28,5
5 11β-hydroxyandrost 670; 680 1190; 1095 670 - 1190
6 11β-gidroxiatilkrahmala 580; 600 945; 946 580 - 946

Example 5 (control)

Determine the longitudinal profile of the volunteer (male, 25 years). Just taken 6 tests with an interval between analyses 10 days. It should be noted that volunteer for the entire observation period (60 days) did not take drugs and not used in a transfusion of blood. Confidence interval values of each specific ES set as in Example 4. On the 61st day of observation with the consent of the volunteer gave him to take the capsule 50 mg of testosterone and the decanoate (Andriol) and capsule DHEA 50 mg Control urine spend 8 hours after administration. Figure 11 and 12 presents the steroid profiles of the test for testosterone and DHEA. It should be noted that in this example, simultaneously determine the longitudinal profile of ES according to the method described in the prototype (hydrolysis of E. coli in phosphate buffer), while the lower limit value profile for testosterone was 32 ng/ml, and DHEA was discovered only after taking the drug.

As can be seen from the description and examples of the method and the comparative and reference examples, the invention provides a reduction in the threshold detection sensitivity of ES, the expansion of the range defined compounds while increasing the reliability of determination of steroid profile.

Sources of information

1. EN 2190853 C2, G01N 33/74, 2002

2. Chem. Pharm. journal, 1988, t, s.

3. EN 2313086 C2, G01N 30/72, 2007.

4. J. Anal. toxicol., 2005, v. 29, No. 4, p.217.

5. WADA Technical Document - TD2004EAAS prototype.

6. Wada Prohibited List, Version 5.0, 2010.

The method of determining the steroid profile in doping control of athletes, including hydrolysis of the sample of urine by an enzyme in the presence of buffer solution and the internal standard, the separation of the hydrolysate, the derivatization him, followed by gas chromatography-mass spectral analysis of the sample and recording the obtained results and definitions n the availability of endogenous steroids (ES), characterized in that in the preparation of the sample hydrolysis of the urine sample is performed with the mixture of two enzymes: β-glucuronidase E.coli and Ukrainian H.pomatia in a volume ratio from 1:1 to 1:3, and the buffer using citrate buffer solution, and the athlete determine ES at least 10-15 times with intervals between tests not less than 10-12 days, based on the test results establish the minimum and maximum quantitative value for each of the identified ES, accept the specified values for the confidence interval and build longitudinal profile of the athlete as a set of confidence intervals all found ES.

 

© 2013-2015 Russian business network RussianPatents.com - Special Russian commercial information project for world wide. Foreign filing in English.